Guidelines for smoking cessation in patients with COPD issued by the Deutsche Gesellschaft für Pneumologie und Beatmungsmedizin;Tabakentwöhnung bei COPD: S3 leitlinie herausgegeben von der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin

Pneumologie

Volumn 62, Issue 5, 2008, Pages 255-272

  Andreas, Stefan ^a,b   Batra, A ^b   Behr, J ^b   Berck, H ^b   Chenot, J F ^b   Gillissen, A ^b   Hering, T ^b   Herth, F ^b   Meierjurgen R ^b   Muhlig S ^b   Nowak, D ^b   Pfeifer, M ^b   Raupach, T ^b   Schultz, K ^b   Sitter, H ^c   Worth, H ^b  

^a Lungenfachklinik Immenhausen   (Germany)

^b Deutsche Gesellschaft für Pneumologie und Beatmungsmedizin eV ^*

^c PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; CLONIDINE; NICOTINE; NORTRIPTYLINE; PLACEBO; VARENICLINE;

ANAMNESIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; DEPRESSION; ECONOMIC ASPECT; EVIDENCE BASED MEDICINE; GENETICS; HUMAN; LUNG FUNCTION; LUNG INFECTION; MORTALITY; MOTIVATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; REVIEW; SMOKING CESSATION; ARTICLE; CLINICAL PRACTICE; COUNSELING; GERMANY; METHODOLOGY; STANDARD;

COUNSELING; GERMANY; GUIDELINE ADHERENCE; HUMANS; PHYSICIAN'S PRACTICE PATTERNS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SMOKING CESSATION;

EID: 45549099970     PISSN: 09348387     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2008-1038148     Document Type: Review

References (251)

1. Bloch RE, Lauterbach K, Oesingmann U et al. Beurteilungskriterien für Leitlinien in der medizinischen Versorgung - Beschlüsse der Vorstände der Bundesärztekammer und Kassenärztlicher Bundesvereinigung, Juni 1997. Deutsches Ärzteblatt 1997; 94: A2154/B-1831/C-1635
2. Phillips B, Ball C, Sacken D. Levels of evidence, http://www.cebm.net/index.aspx?o=1025. Oxford. Centre for Evidence-based Medicine, 2001
3. Abholz HH, Gillissen A, Magnussen H et al. Nationale VersorgungsLeitlinie COPD, Langfassung, Version 1.2. In: Bundesärztekammer (BÄK) Arbeitsgemeinschaft der Deutschen Ärztekammern, Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF), 2006
4. Forsyth L, Graham K, Harbour RT et al. SIGN 50: A guideline developers' handbook. Edinburgh: Scottish Intercollegiate Guidlines Network, 2004
5. Bundesärztekammer (BÄK), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF), Kassenärztliche Bundesvereinigung (KBV). Nationales Programm für Versorgungs- Leitlinien. Methoden-Report, 2004
6. Tonnesen P, Carrozzi L, Fagerstrom KO et al. Smoking cessation in patients with respiratory diseases: a high priority, integral component of therapy. Eur Respir J 2007; 29: 390-417
7. Vogelmeier C, Buhl R, Criée CP et al. Guidelines for the diagnosis and therapy of COPD issued by Deutsche Atemwegsliga and Deutsche Gesellschaft fur Pneumologie und Beatmungsmedizin. Pneumologie 2007; 61: 1-40
8. Pauwels RA, Buist AS, Calverley PM et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med 2001; 163: 1256-1276
9. Rabe KF, Hurd S, Anzueto A et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007; 176: 532-555
10. Aigner K, Homeier I, Koessler W et al. Standards der Raucherentwöhnung, Konsensus der ÖGP. Wiener Klinische Wochenschrift 2005; 117 Supplement 2: 1-22
11. National Health Committee. Guidelines for Smoking Cessation. Wellington, New Zealand, 2004
12. National Collaborating Centre for Chronic Conditions, (NICE). Chronic obstructive pulmonary disease. National clinical guideline on management of chronic obstructive pulmonary disease in adults in primary and secondary care. Thorax 2004; 59: 1-232
13. West R, McNeill A, Raw M. Smoking Cessation Guidelines for Scotland: 2004 Update. In: NHS Health Scotland and ASH Scotland, 2004
14. Batra A, Lindinger P, Schütz C. Tabakbedingte Störungen "Leitlinie Tabakentwöhnung". In: Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften, 2004
15. Anderson JE, Jorenby DE, Scott WJ et al. Treating Tobacco Use and Dependence: An Evidence-Based Clinical Practice Guideline for Tobacco Cessation. Chest 2002; 121: 932-941
16. Orsetti K. Smoking Cessation Guideline. In: University of Michigan Health System, 2001
17. Bundesärztekammer, Kassenärztliche Bundesvereinigung. Checkliste Methodische Qualität von Leitlinien, 2. Version (8/1999). Deutsches Ärzteblatt 2000; 97: A1170
18. Parrott S, Godfrey C. Economics of smoking cessation. Bmj 2004; 328: 947-949
19. Fiore MC. Treating tobacco use and dependence: an introduction to the US Public Health Service Clinical Practice Guideline. Respir Care 2000; 45: 1196-1199
20. U.S. Department of Health and Human Services. Reducing Tobacco Use: A Report of the Surgeon General. Atlanta, Georgia: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, 2000
21. Rosser W, Tremblay M. Smoking Cessation Guidelines. In: Pegasus Healthcare International, 2000
22. West R, McNeill A, Raw M. Smoking cessation guidelines for health professionals: an update. Health Education Authority. Thorax 2000; 55: 987-999
23. Parrott S, Godfrey C, Raw M et al. Guidance for commissioners on the cost effectiveness of smoking cessation interventions. Health Educational Authority. Thorax 1998; 53 Suppl 5: S1-38
24. Raw M, McNeill A, West R. Smoking Cessation Guidelines for Health Professionals - A guide to effective smoking cessation interventions for the health care system. Thorax 1998; 53: 1-18
25. Arzneimittelkommission der deutschen Ärzteschaft. Empfehlungen zur Therapie der Tabakabhängigkeit. Suchtmed 2001; 3: 156-175
26. Hoch E, Mühlig S, Nowak D et al. Rauchen und Nikotinabhängigkeit in Deutschland: Eine klinisch-epidemiologische Perspektive. Zeitschrift für klinische Psychologie und Psychotherapie (in press),
27. Lampen T, Burger M. Verbreitung und Strukturen des Tabakkonsums in Deutschland. Bundesgesundheitsbl - Gesundheitsforsch - Gesundheitsschutz 2005; 48: 1231-1241
28. Janson C, Kunzli N, de Marco R et al. Changes in active and passive smoking in the European Community Respiratory Health Survey. Eur Respir J 2006; 27: 517-524
29. Miller CH, Burgoon M, Grandpre JR et al. Identifying principal risk factors for the initiation of adolescent smoking behaviors: the significance of psychological reactance. Health Commun 2006; 19: 241-252
30. Schumann A, Hapke U, Meyer C et al. Prevalence, characteristics, associated mental disorders and predictors of DSM-IV nicotine dependence. Eur Addict Res 2004; 10: 29-34
31. Rounsaville BJ, Bryant K, Babor T et al. Cross system agreement for substance use disorders: DSM-III-R, DSM-IV and ICD-10. Addiction 1993; 88: 337-348
32. Watkins SS, Koob GF, Markou A. Neural mechanisms underlying nicotine addiction: acute positive reinforcement and withdrawal. Nicotine Tob Res 2000; 2: 19-37
33. Di Chiara G, Imperato A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci U S A 1988; 85: 5274-5278
34. Balfour DJ. Neural mechanisms underlying nicotine dependence. Addiction 1994; 89: 1419-1423
35. Dani JA, Heinemann S. Molecular and cellular aspects of nicotine abuse. Neuron 1996; 16: 905-908
36. Corrigall WA, Franklin KB, Coen KM et al. The mesolimbic dopaminer gic system is implicated in the reinforcing effects of nicotine. Psychopharmacology (Berl) 1992; 107: 285-289
37. Nelson CB, Wittchen HU. Smoking and nicotine dependence. Results from a sample of 14- to 24-year-olds in Germany. Eur Addict Res 1998; 4: 42-49
38. Centers for Disease Control and Prevention (CDC). Cigarette smoking among adults - United States, 1995. MMWR Morb Mortal Wkly Rep 1997; 46: 1217-1220
39. West R, Sohal T. "Catastrophic" pathways to smoking cessation: findings from national survey. Bmj 2006; 332: 458-460
40. Hughes JR, Hatsukami D. Signs and symptoms of tobacco withdrawal. Arch Gen Psychiatry 1986; 43: 289-294
41. Le Foll B, Goldberg SR. Nicotine as a typical drug of abuse in experimental animals and humans. Psychopharmacology (Berl) 2006; 184: 367-381
42. Malin DH, Lake JR, Carter VA et al. Naloxone precipitates nicotine abstinence syndrome in the rat. Psychopharmacology (Berl) 1993; 112: 339-342
43. Epping-Jordan MP, Watkins SS, Koob GF et al. Dramatic decreases in brain reward function during nicotine withdrawal. Nature 1998; 393: 76-79
44. Benwell ME, Balfour DJ, Anderson JM. Evidence that tobacco smoking increases the density of (-)-[3H]nicotine binding sites in human brain. J Neurochem 1988; 50: 1243-1247
45. Breese CR, Marks MJ, Logel J et al. Effect of smoking history on [3H]nicotine binding in human postmortem brain. J Pharmacol Exp Ther 1997; 282: 7-13
46. Perry DC, Davila-Garcia MI, Stockmeier CA et al. Increased nicotinic receptors in brains from smokers: membrane binding and autoradiography studies. J Pharmacol Exp Ther 1999; 289: 1545-1552
47. Benwell ME, Balfour DJ. Effects of nicotine administration and its withdrawal on plasma corticosterone and brain 5-hydroxyindoles. Psychopharmacology (Berl) 1979; 63: 7-11
48. Benwell ME, Balfour DJ. The effects of nicotine administration on 5-HT uptake and biosynthesis in rat brain. Eur J Pharmacol 1982; 84: 71-77
49. Fidler JA, Wardle J, Brodersen NH et al. Vulnerability to smoking after trying a single cigarette can lie dormant for three years or more. Tob Control 2006; 15: 205-209
50. Church DF, Pryor WA. Free-radical chemistry of cigarette smoke and its toxicological implications. Environ Health Perspect 1985; 64: 111-126
51. Church DF, Pryor WA. The oxidative stress placed on the lung by cigarette smoke. In: Crystal RG, West JB (eds). The Lung NY: Raven Press, 1991: 1975-1979
52. MacNee W, Wiggs B, Belzberg AS et al. The effect of cigarette smoking on neutrophil kinetics in human lungs. N Engl J Med 1989; 321: 924-928
53. Nadel JA. Role of neutrophil elastase in hypersecretion during COPD exacerbations, and proposed therapies. Chest 2000; 117: 386S-389S
54. Walsh DE, Greene CM, Carroll TP et al. Interleukin-8 up-regulation by neutrophil elastase is mediated by MyD88/IRAK/TRAF-6 in human bronchial epithelium. J Biol Chem 2001; 276: 35494-35499
55. Shapiro SD. Diverse roles of macrophage matrix metalloproteinases in tissue destruction and tumor growth. Thromb Haemost 1999; 82: 846-849
56. Arcavi L, Benowitz NL. Cigarette smoking and infection. Arch Intern Med 2004; 164: 2206-2216
57. Dye JA, Adler KB. Effects of cigarette smoke on epithelial cells of the respiratory tract. Thorax 1994; 49: 825-834
58. Marcy TW, Merrill WW. Cigarette smoking and respiratory tract infection. Clin Chest Med 1987; 8: 381-391
59. Kalra R, Singh SP, Savage SM et al. Effects of cigarette smoke on immune response: chronic exposure to cigarette smoke impairs antigen-mediated signaling in T cells and depletes IP3-sensitive Ca(2+) stores. J Pharmacol Exp Ther 2000; 293: 166-171
60. Gerrard JW, Heiner DC, Ko CG et al. Immunoglobulin levels in smokers and non-smokers. Ann Allergy 1980; 44: 261-262
61. U.S. Department of Health and Human Services. The Health Consequences of Smoking: A Report of the Surgeon General. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, 2004
62. Lebowitz MD. Smoking habits and changes in smoking habits as they relate to chronic conditions and respiratory symptoms. Am J Epidemiol 1977; 105: 534-543
63. Walraven GE, Nyan OA, Sande MA van der et al. Asthma, smoking and chronic cough in rural and urban adult communities in The Gambia. Clin Exp Allergy 2001; 31: 1679-1685
64. Troisi RJ, Speizer FE, Rosner B et al. Cigarette smoking and incidence of chronic bronchitis and asthma in women. Chest 1995; 108: 1557-1561
65. Pilotto LS, Smith BJ, Nitschke M et al. Industry, air quality, cigarette smoke and rates of respiratory illness in Port Adelaide. Aust N Z J Public Health 1999; 23: 657-660
66. Tobacco smoking. IARC Monogr Eval Carcinog Risk Chem Hum 1986; 38: 35-394
67. Doll R, Hill AB. The mortality of doctors in relation to their smoking habits; a preliminary report. Br Med J 1954; 1: 1451-1455
68. Bouchardy C, Benhamou S, Jourenkova N et al. Metabolic genetic polymorphisms and susceptibility to lung cancer. Lung Cancer 2001; 32: 109-112
69. Doll R, Peto R, Boreham J et al. Mortality in relation to smoking: 50 years' observations on male British doctors. Bmj 2004; 328: 1519
70. Piipari R, Jaakkola JJ, Jaakkola N et al. Smoking and asthma in adults. Eur Respir J 2004; 24: 734-739
71. Senthilselvan A, Chen Y, Dosman JA. Predictors of asthma and wheezing in adults. Grain farming, sex, and smoking. Am Rev Respir Dis 1993; 148: 667-670
72. Godtfredsen NS, Lange P, Prescott E et al. Changes in smoking habits and risk of asthma: a longitudinal population based study. Eur Respir J 2001; 18: 549-554
73. Eisner MD, Klein J, Hammond SK et al. Directly measured second hand smoke exposure and asthma health outcomes. Thorax 2005; 60: 814-821
74. Gilliland FD, Islam T, Berhane K et al. Regular smoking and asthma incidence in adolescents. Am J Respir Crit Care Med 2006; 174: 1094-1100
75. Genuneit J, Weinmayr G, Radon K et al. Smoking and the incidence of asthma during adolescence: results of a large cohort study in Germany. Thorax 2006; 61: 572-578
76. Piitulainen E, Sveger T. Effect of environmental and clinical factors on lung function and respiratory symptoms in adolescents with alphal-antitrypsin deficiency. Acta Paediatr 1998; 87: 1120-1124
77. Braman SS. Chronic cough due to chronic bronchitis: ACCP evidence-based clinical practice guidelines. Chest 2006; 129: 104S-115S
78. Andersen A, Berge SR, Engeland A et al. Exposure to nickel compounds and smoking in relation to incidence of lung and nasal cancer among nickel refinery workers. Occup Environ Med 1996; 53: 708-713
79. Blake GH, Abell TD, Stanley WG. Cigarette smoking and upper respiratory infection among recruits in basic combat training. Ann Intern Med 1988; 109: 198-202
80. Cohen S, Tyrrell DA, Russell MA et al. Smoking, alcohol consumption, and susceptibility to the common cold. Am J Public Health 1993; 83: 1277-1283
81. Plaschke PP, Janson C, Norrman E et al. Onset and remission of allergic rhinitis and asthma and the relationship with atopic sensitization and smoking. Am J Respir Crit Care Med 2000; 162: 920-924
82. Nuorti JP, Butler JC, Farley MM et al. Cigarette smoking and invasive pneumococcal disease. Active Bacterial Core Surveillance Team. N Engl J Med 2000; 342: 681-689
83. Almirall J, Gonzalez CA, Balanzo X et al. Proportion of community-acquired pneumonia cases attributable to tobacco smoking. Chest 1999; 116: 375-379
84. Straus WL, Plouffe JF, File JrTM et al. Risk factors for domestic acquisition of legionnaires disease. Ohio legionnaires Disease Group. Arch Intern Med 1996; 156: 1685-1692
85. Kark JD, Lebiush M, Rannon L. Cigarette smoking as a risk factor for epidemic a(h1n1) influenza in young men. N Engl J Med 1982; 307: 1042-1046
86. Buskin SE, Gale JL, Weiss NS et al. Tuberculosis risk factors in adults in King County, Washington, 1988 through 1990. Am J Public Health 1994; 84: 1750-1756
87. Alcaide J, Altet MN, Plans P et al. Cigarette smoking as a risk factor for tuberculosis in young adults: a case-control study. Tuber Lung Dis 1996; 77: 112-116
88. Ryu JH, Colby TV, Hartman TE et al. Smoking-related interstitial lung diseases: a concise review. Eur Respir J 2001; 17: 122-132
89. Katzenstein AL, Myers JL. Idiopathic pulmonary fibrosis: clinical relevance of pathologic classification. Am J Respir Crit Care Med 1998; 157: 1301-1315
90. Coultas DB, Zumwalt RE, Black WC et al. The epidemiology of interstitial lung diseases. Am J Respir Crit Care Med 1994; 150: 967-972
91. Johnston ID, Prescott RJ, Chalmers JC et al. British Thoracic Society study of cryptogenic fibrosing alveolitis: current presentation and initial management. Fibrosing Alveolitis Subcommittee of the Research Committee of the British Thoracic Society. Thorax 1997; 52: 38-44
92. Marshall RP, Puddicombe A, Cookson WO et al. Adult familial cryptogenic fibrosing alveolitis in the United Kingdom. Thorax 2000; 55: 143-146
93. Schwartz DA, Merchant RK, Helmers RA et al. The influence of cigarette smoking on lung function in patients with idiopathic pulmonary fibrosis. Am Rev Respir Dis 1991; 144: 504-506
94. Baumgartner KB, Samet JM, Stidley CA et al. Cigarette smoking: a risk factor for idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1997; 155: 242-248
95. Hubbard R, Venn A, Lewis S et al. Lung cancer and cryptogenic fibrosing alveolitis. A population-based cohort study. Am J Respir Crit Care Med 2000; 161: 5-8
96. Hartman TE, Primack SL, Kang FY et al. Disease progression in usual interstitial pneumonia compared with desquamative interstitial pneumonia. Assessment with serial CT. Chest 1996; 110: 378-382
97. Yousem SA, Colby TV, Gaensler EA. Respiratory bronchiolitis- associated interstitial lung disease and its relationship to desquamative interstitial pneumonia. Mayo Clin Proc 1989; 64: 1373-1380
98. Niewoehner DE, Kleinerman J, Rice DB. Pathologic changes in the peripheral airways of young cigarette smokers. N Engl J Med 1974; 291: 755-758
99. Myers JL, Veal CCF, Shin MS et al. Respiratory bronchiolitis causing interstitial lung disease. A clinicopathologic study of six cases. Am Rev Respir Dis 1987; 135: 880-884
100. Favara BE, Feller AC, Pauli M et al. Contemporary classification of histiocytic disorders. The WHO Committee On Histiocytic/Reticulum Cell Proliferations. Reclassification Working Group of the Histiocyte Society. Med Pediatr Oncol 1997; 29: 157-166
101. Hance AJ, Basset F, Saumon G et al. Smoking and interstitial lung disease. The effect of cigarette smoking on the incidence of pulmonary histiocytosis X and sarcoidosis. Ann N Y Acad Sci 1986; 465: 643-656
102. Casolaro MA, Bernaudin JF, Saltini C et al. Accumulation of Langerhans' cells on the epithelial surface of the lower respiratory tract in normal subjects in association with cigarette smoking. Am Rev Respir Dis 1988; 137: 406-411
103. Westedt ML, Hazes JM, Breedveld FC et al. Cigarette smoking and pulmonary diffusion defects in rheumatoid arthritis. Rheumatol Int 1998; 18: 1-4
104. Wolfe F. The effect of smoking on clinical, laboratory, and radiographic status in rheumatoid arthritis. J Rheumatol 2000; 27: 630-637
105. Banks J, Banks C, Cheong B et al. An epidemiological and clinical investigation of pulmonary function and respiratory symptoms in patients with rheumatoid arthritis. Q J Med 1992; 85: 795-806
106. Hyland RH, Gordon DA, Broder I et al. A systematic controlled study of pulmonary abnormalities in rheumatoid arthritis. J Rheumatol 1983; 10: 395-405
107. Merkel F, Pullig O, Marx M et al. Course and prognosis of anti-basement membrane antibody (anti-BM-Ab)-mediated disease: report of 35 cases. Nephrol Dial Transplant 1994; 9: 372-376
108. Kelly PT, Haponik EF. Goodpasture syndrome: molecular and clinical advances. Medicine (Baltimore) 1994; 73: 171-185
109. Pauwels RA, Rabe KF. Burden and clinical features of chronic obstructive pulmonary disease (COPD). Lancet 2004; 364: 613-620
110. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 1997; 349: 1498-1504
111. Behr J, Nowak D. Tobacco smoke and respiratory disease. In: d'Amato G, Holgate S (eds). European Respiratory Monograph (7) The impact of air pollution on respiratory health. ERS 2002; 21: 161-179
112. European Commission. Tobacco or Health in the European Union - past, present and future. The ASPECT Consortium. Luxembourg: Office for Official Publications of the European Communities, 2004
113. Shahab L, Jarvis MJ, Britton JR et al. Prevalence, diagnosis and relation to tobacco dependence of chronic obstructive pulmonary disease in a nationally representative population sample. Thorax 2006; 61: 1043-1047
114. Criée CP, Novak D. Einsparpotential durch Prävention bei COPD.In: Schauder P, Berthold H, Eckel H, Ollenschläger G (eds). Zukunft sichern: Senkung der Zahl chronisch Kranker, Verwirklichung einer realistischen Utopie. Köln: Deutscher Ärzteverlag, 2006: 205-208
115. de Marco R, Accordini S, Cerveri I et al. An international survey of chronic obstructive pulmonary disease in young adults according to GOLD stages. Thorax 2004; 59: 120-125
116. Chapman KR, Mannino DM, Soriano JB et al. Epidemiology and costs of chronic obstructive pulmonary disease. Eur Respir J 2006; 27: 188-207
117. Nowak D, Berger K, Lippert B et al. Epidemiology and health economics of COPD across Europe: a critical analysis. Treat Respir Med 2005; 4: 381-395
118. Buist AS, McBurnie MA, Vollmer WM et al. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet 2007; 370: 741-750
119. Burney P. The pharmacoepidemiology of COPD: Recent advances and methodological discussion. Eur Respir J 2003; 22: 1S-44S
120. Lundback B, Lindberg A, Lindstrom M et al. Not 15 but 50% of smokers develop COPD? - Report from the Obstructive Lung Disease in Northern Sweden Studies. Respir Med 2003; 97: 115-122
121. Wedzicha JA, Donaldson GC. Exacerbations of chronic obstructive pulmonary disease. Respir Care 2003; 48: 1204-1213; discussion 1213-1205
122. Lundback B, Gulsvik A, Albers M et al. Epidemiological aspects and early detection of chronic obstructive airway diseases in the elderly. Eur Respir J Suppl 2003; 40: 3s-9s
123. Lokke A, Lange P, Scharling H et al. Developing COPD: a 25 year follow up study of the general population. Thorax 2006; 61: 935-939
124. Prescott E, Bjerg AM, Andersen PK et al. Gender difference in smoking effects on lung function and risk of hospitalization for COPD: results from a Danish longitudinal population study. Eur Respir J 1997; 10: 822-827
125. Xu X, Li B, Wang L. Gender difference in smoking effects on adult pulmonary function. Eur Respir J 1994; 7: 477-483
126. Chapman KR. Chronic obstructive pulmonary disease: are women more susceptible than men? Clinics in Chest Medicine 2004; 25: 331-341
127. Cookson WO. State of the art. Genetics and genomics of chronic obstructive pulmonary disease. Proc Am Thorac Soc 2006; 3: 473-475
128. Rennard SI, Vestbo J. COPD: the dangerous underestimate of 15%. Lancet 2006; 367: 1216-1219
129. Falk GA, Briscoe WA. Alpha-1-antitrypsin deficiency in chronic obstructive pulmonary disease. Ann Intern Med 1970; 72: 427-429
130. Wouters EF. Chronic obstructive pulmonary disease. 5: systemic effects of COPD. Thorax 2002; 57: 1067-1070
131. Reid MB. COPD as a muscle disease. Am J Respir Crit Care Med 2001; 164: 1101-1102
132. Anthonisen NR, Skeans MA, Wise RA et al. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann Intern Med 2005; 142: 233-239
133. Andreas S, Anker SD, Scanlon PD et al. Neurohumoral activation as a link to systemic manifestation of chronic lung disease. Chest 2005; 128: 3618-3624
134. Yanbaeva DG, Dentener MA, Creutzberg EC et al. Systemic Effects of Smoking. Chest 2007; 131: 1557-1566
135. Cerveri I, Accordini S, Corsico A et al. Chronic cough and phlegm in young adults. Eur Respir J 2003; 22: 413-417
136. 1 decline and chronic obstructive pulmonary disease morbidity. Copenhagen City Heart Study Group. Am J Respir Crit Care Med 1996; 153: 1530-1535
137. 1 by age and smoking status: facts, figures, and fallacies. Thorax 1997; 52: 820-827
138. Fletcher C, Peto R. The natural history of chronic airflow obstruction. Br Med J 1977; 1: 1645-1648
139. Gold DR, Wang X, Wypij D et al. Effects of cigarette smoking on lung function in adolescent boys and girls. N Engl J Med 1996; 335: 931-937
140. Sherrill DL, Lebowitz MD, Knudson RJ et al. Smoking and symptom effects on the curves of lung function growth and decline. Am Rev Respir Dis 1991; 144: 17-22
141. 1: new insight into gender differences. Eur Respir J 1994; 7: 1056-1061
142. Anthonisen NR. Lung Health Study. Am Rev Respir Dis 1989; 140: 871-872
143. Anthonisen NR, Connett JE, Enright PL et al. Hospitalizations and mortality in the Lung Health Study. Am J Respir Crit Care Med 2002; 166: 333-339
144. Anthonisen NR, Lindgren PG, Tashkin DP et al. Bronchodilator response in the lung health study over 11 yrs. Eur Respir J 2005; 26: 45-51
145. Scanlon PD, Connett JE, Waller LA et al. Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease. The Lung Health Study. Am J Respir Crit Care Med 2000; 161: 381-390
146. Viegi G, Paoletti P, Carrozzi L et al. CO diffusing capacity in a general population sample: relationships with cigarette smoking and airflow obstruction. Respiration 1993; 60: 155-161
147. Viegi G, Sherrill DL, Carrozzi L et al. An 8-year follow-up of carbon monoxide diffusing capacity in a general population sample of northern italy. Chest 2001; 120: 74-80
148. Verbanck S, Schuermans D, Paiva M et al. Small airway function improvement after smoking cessation in smokers without airway obstruction. Am J Respir Crit Care Med 2006; 174: 853-857
149. Willemse BW, Postma DS, Timens W et al. The impact of smoking cessation on respiratory symptoms, lung function, airway hyperresponsiveness and inflammation. Eur Respir J 2004; 23: 464-476
150. Willemse BW, ten Hacken NH, Rutgers B et al. Smoking cessation improves both direct and indirect airway hyperresponsiveness in COPD. Eur Respir J 2004; 24: 391-396
151. Magnussen H, Goeckenjan G, Kohler D et al. Guidelines to long-term oxygen therapy. Pneumologie 2001; 55: 454-464
152. Lacasse Y, LaForge J, Maltais F. Got a match? Home oxygen therapy in current smokers. Thorax 2006; 61: 374-375
153. Heidrich J, Wellmann J, Heuschmann PU et al. Mortality and morbidity from coronary heart disease attributable to passive smoking. Eur Heart J 2007; 28: 2498-2502
154. European Respiratory Society. Lifting the smokescreen. Brussels: European Respiratory Society, 2006
155. Jaakkola MS, Jaakkola JJ. Impact of smoke-free workplace legislation on exposures and health: possibilities for prevention. Eur Respir J 2006; 28: 397-408
156. Lam TH, Ho LM, Hedley AJ et al. Secondhand smoke and respiratory ill health in current smokers. Tob Control 2005; 14: 307-314
157. Raupach T, Radon K, Nowak D et al. Passive Smoking - Health Consequences and Effects of Exposure Prevention. Pneumologie 2008; 62: 44-50
158. Jimenez-Ruiz CA, Masa F, Miravitlles M et al. Smoking characteristics: differences in attitudes and dependence between healthy smokers and smokers with COPD. Chest 2001; 119: 1365-1370
159. Jimenez-Ruiz C, Miravitlles M, Sobradillo V et al. Can cumulative tobacco consumption, FTND score, and carbon monoxide concentration in expired air be predictors of chronic obstructive pulmonary disease? Nicotine Tob Res 2004; 6: 649-653
160. Hertzen L von, Reunanen A, Impivaara O et al. Airway obstruction in relation to symptoms in chronic respiratory disease - a nationally representative population study. Respiratory Medicine 2000; 94: 356-363
161. Medici TC, Unger S, Ruegger M. Smoking pattern of smokers with and without tobacco-smoke-related lung diseases. Am Rev Respir Dis 1985; 131: 385-388
162. Killen J, Fortmann S, Kraemer H et al. Who will relapse? Symptoms of nicotine dependence predict long-term relapse after smoking cessation. J Consult Clin Psychol 1992; 60: 797-801
163. Clark KD, Wardrobe-Wong N, Eiliott JJ et al. Cigarette smoke inhalation and lung damage in smoking volunteers. Eur Respir J 1998; 12: 395-399
164. Wagena EJ, Huibers MJ, Schayck CP van. Antidepressants in the treatment of patients with COPD: possible associations between smoking cigarettes, COPD and depression. Thorax 2001; 56: 587-588
165. Manen JG van, Bindels PJE, Dekker FW et al. Risk of depression in patients with chronic obstructive pulmonary disease and its determinants. Thorax 2002; 57: 412-416
166. Wagena EJ, Meer RM van der, Ostelo RJ et al. The efficacy of smoking cessation strategies in people with chronic obstructive pulmonary disease: results from a systematic review. Respir Med 2004; 98: 805-815
167. Yohannes AM, Roomi J, Baldwin RC et al. Depression in elderly outpatients with disabling chronic obstructive pulmonary disease. Age and Ageing 1998; 27: 155-160
168. Dudley D, Glaser E, Jorgenson B et al. Psychosocial concomitants to rehabilitation in chronic obstructive pulmonary disease. 3. Dealing with psychiatric disease (as distinguished from psychosocial or psychophysiologic problems). Chest 1980; 77: 667
169. Isoaho R, Puolijoki H, Huhti E et al. Chronic obstructive pulmonary disease and self-maintaining functions in the elderly - a population-based study. Scand J Prim Health Care 1995; 13: 122-127
170. O'Neill E. Illness representations and coping of women with chronic obstructive pulmonary disease: a pilot study. Heart Lung 2002; 31: 295-302
171. DiMarco F, Verga M, Reggente M et al. Anxiety and depression in COPD patients: The roles of gender and disease severity. Respir Med 2006; 100: 1767-1774
172. Ng TP, Niti M, Tan WC et al. Depressive symptoms and chronic obstructive pulmonary disease: effect on mortality, hospital readmission, symptom burden, functional status, and quality of life. Arch Intern Med 2007; 167: 60-67
173. Hughes J, Stead L, Lancaster T. Antidepressants for smoking cessation. Cochrane Database Syst Rev, 2004: CD000031
174. Breslau N, Johnson EO, Hiripi E et al. Nicotine Dependence in the United States - Prevalence, Trends, and Smoking Persistence. Arch Gen Psychiatry 2001; 58: 810-816
175. Glassman AH, Covey LS, Stetner F et al. Smoking cessation and the course of major depression: a follow-up study. Lancet 2001; 357: 1929-1932
176. Breslau N, Peterson EL, Schultz LR et al. Major Depression and Stages of Smoking. A Longitudinal Investigation 1998; 55: 161-166
177. Dierker L, Avenevoli S, Stolar M et al. Smoking and depression: an examination of mechanisms of comorbidity. Am J Psychiatry 2002; 159: 947-953
178. Covey L, Glassman A, Stetner F. Cigarette smoking and major depression. J Addict Dis 1998; 17: 35-46
179. Wilhelm K, Arnold K, Niven H et al. Grey lungs and blue moods: smoking cessation in the context of lifetime depression history. Aust N Z J Psychiatry 2004; 38: 896-905
180. Breslau N. Psychiatric comorbidity of smoking and nicotine dependence. Behav Genet 1995; 25: 95-101
181. John U, Meyer C, Rumpf HJ et al. Smoking, nicotine dependence and psychiatric comorbidity - a population-based study including smoking cessation after three years. Drug Alcohol Depend 2004; 76: 287-295
182. Haug NA, Heinberg LJ, Guarda AS. Cigarette smoking and its relationship to other substance use among eating disordered inpatients. Eat Weight Disord 2001; 6: 130-139
183. Kordon A, Kahl KG. Attention-deficit/hyperactivity disorder (ADHS) in adulthood. Psychother Psychosom Med Psychol 2004; 54: 124-136
184. Anthonisen NR, Connett JE, Murray RP. Smoking and lung function of Lung Health Study participants after 11 years. Am J Respir Crit Care Med 2002; 166: 675-679
185. Heatherton TF, Kozlowski LT, Frecker RC et al. The Fagerstrom-Test for Nicotine Dependence: a revision of the Fagerstrom Tolerance Questionnaire. Br J Addict 1991; 86: 1119-1127
186. Anda RF, Williamson DF, Escobedo LG et al. Depression and the dynamics of smoking. A national perspective. Jama 1990; 264: 1541-1545
187. Killen JD, Fortmann SP, Kraemer HC et al. Interactive effects of depression symptoms, nicotine dependence, and weight change on late smoking relapse. J Consult Clin Psychol 1996; 64: 1060-1067
188. Herrmann C, Buss U. Vorstellung und Validierung einer deutschen Version der "Hospital Anxiety and Depression Scale" (HAD-Skala); ein Fragebogen zur Erfassung des psychischen Befindens bei Patienten mit körperlichen Beschwerden. Diagnostica 1994; 40: 143-154
189. Löwe B. PHQ-D - Gesundheitsfragebogen für Patienten. In: Schumacher J, Strauss B (eds). Klinische Interviews und Ratingskalen Göttingen: Hogrefe, 2004: 321-327
190. Riemann K, Gerber U. Standardisierung von Fragestellungen zum Rauchen: ein Beitrag zur Qualitätssicherung in der Prä ventionsforschung. 4 ed: BZgA. Köln: Bundeszentrale für gesundheitliche Aufklärung, 2000
191. Hilberink SR, Jacobs JE, Schlosser M et al. Characteristics of patients with COPD in three motivational stages related to smoking cessation. Patient Educ Couns 2006; 61: 449-457
192. Bize R, Burnand B, Mueller Y et al. Biomedical risk assessment as an aid for smoking cessation. Cochrane Database Syst Rev, 2005: CD004705
193. West R, Hajek P, Stead L et al. Outcome criteria in smoking cessation trials: proposal for a common standard. Addiction 2005; 100: 299-303
194. Brandt CJ, Ellegaard H, Joensen M et al. Effect of diagnosis of "smoker's lung". RYLUNG Group. Lancet 1997; 349: 253
195. 1 and asbestos exposure. Eur Respir J 1998; 11: 284-290
196. Walters N, Coleman T. Comparison of the smoking behaviour and attitudes of smokers who attribute respiratory symptoms to smoking with those who do not. Br J Gen Pract 2002; 52: 132-134
197. Bednarek M, Gorecka D, Wielgomas J et al. Smokers with airway
198. Gorecka D, Bednarek M, Nowinski A et al. Diagnosis of airflow limitation combined with smoking cessation advice increases stop-smoking rate. Chest 2003; 123: 1916-1923
199. Townsend CO, Clark MM, Jett JR et al. Relation between smoking cessation and receiving results from three annual spiral chest computed tomography scans for lung carcinoma screening. Cancer 2005; 103: 2154-2162
200. A clinical practice guideline for treating tobacco use and dependence: A US Public Health Service report. Jama 2000; 283: 3244-3254
201. Soria R, Legido A, Escolano C et al. A randomised controlled trial of motivational interviewing for smoking cessation. Br J Gen Pract 2006; 56: 768-774
202. Miller WR. Motivational interviewing: research, practice, and puzzles. Addict Behav 1996; 21: 835-842
203. O'Hara P, Grill J, Rigdon MA et al. Design and results of the initial intervention program for the Lung Health Study. The Lung Health Study Research Group. Prev Med 1993; 22: 304-315
204. 1. The Lung Health Study. Jama 1994; 272: 1497-1505
205. Godtfredsen NS, Vestbo J, Osler M et al. Risk of hospital admission for COPD following smoking cessation and reduction: a Danish population study. Thorax 2002; 57: 967-972
206. 1 decline in current smokers but not ex-smokers with mild chronic obstructive pulmonary disease: results from the lung health study. Am J Respir Crit Care Med 2001; 164: 358-364
207. Jo YH, Talmage DA, Role LW. Nicotinic receptor-mediated effects on appetite and food intake. J Neurobiol 2002; 53: 618-632
208. Williamson DF, Madans J, Anda RF et al. Smoking cessation and severity of weight gain in a national cohort. N Engl J Med 1991; 324: 739-745
209. Flegal KM, Troiano RP, Pamuk ER et al. The influence of smoking cessation on the prevalence of overweight in the United States. N Engl J Med 1995; 333: 1165-1170
210. Carroll ME, Meisch RA. Increased drug-reinforced behaviour due to food deprivation. In: Thompson T, Dews PB, JE B (eds). Advances in Behavioural Pharmacology. Orlando: Academic Press Inc. 1984: 47-88
211. Swan GE, Carmelli D. Characteristics associated with excessive weight gain after smoking cessation in men. Am J Public Health 1995; 85: 73-77
212. Pomerleau CS, Zucker AN, Stewart AJ. Characterizing concerns about post-cessation weight gain: results from a national survey of women smokers. Nicotine Tob Res 2001; 3: 51-60
213. Hughes JR, Gust SW, Skoog K et al. Symptoms of tobacco withdrawal. A replication and extension. Arch Gen Psychiatry 1991; 48: 52-59
214. Pisinger C, Jorgensen T. Weight concerns and smoking in a general population: the Inter99 study. Prev Med 2007; 44: 283-289
215. Nordstrom BL Kinnunen T, Utman CH et al. Long-term effects of nicotine gum on weight gain after smoking cessation. Nicotine Tob Res 1999; 1: 259-268
216. Hays JT, Hurt RD, Rigotti NA et al. Sustained-release bupropion for pharmacologic relapse prevention after smoking cessation, a randomized, controlled trial. Ann Intern Med 2001; 135: 423-433
217. Marcus BH, Albrecht AE, King TK et al. The efficacy of exercise as an aid for smoking cessation in women: a randomized controlled trial. Arch Intern Med 1999; 159: 1229-1234
218. Kadowaki T, Watanabe M, Okayama A et al. Continuation of smoking cessation and following weight change after intervention in a healthy population with high smoking prevalence. J Occup Health 2006; 48: 402-406
219. 1. Eur Respir J 1989; 2: 811-816
220. 1: results from the Lung Health Study. Eur Respir J 2005; 25: 1011-1017
221. Sherrill DL, Enright P, Cline M et al. Rates of decline in lung function among subjects who restart cigarette smoking. Chest 1996; 109: 1001-1005
222. Bolliger CT, Zellweger JP, Danielsson T et al. Influence of long-term smoking reduction on health risk markers and quality of life. Nicotine Tob Res 2002; 4: 433-439
223. Tverdal A, Bjartveit K. Health consequences of reduced daily cigarette consumption. Tobacco Control 2006; 15: 472-480
224. Raupach T, Shahab L, Neubert K et al. Implementing a hospital-based smoking cessation programme: Evidence for a learning effect. Patient Educ Couns, 2008 (in press)
225. Wagena EJ, Zeegers MP, Schayck CP van et al. Benefits and risks of pharmacological smoking cessation therapies in chronic obstructive pulmonary disease. Drug Saf 2003; 26: 381-403
226. van der Meer RM, Wagena EJ, Ostelo RW et al. Smoking cessation for chronic obstructive pulmonary disease. Cochrane Database Syst Rev, 2003: CD002999
227. Tashkin D, Kanner R, Bailey W et al. Smoking cessation in patients with chronic obstructive pulmonary disease: a double-blind, placebo-controlled, randomised trial. Lancet 2001; 357: 1571-1575
228. Tonnesen P, Mikkelsen K, Bremann L. Nurse-conducted smoking cessation in patients with COPD using nicotine sublingual tablets and behavioral support. Chest 2006; 130: 334-342
229. Wagena EJ, Knipschild PG, Huibers MJH et al. Efficacy of Bupropion and Nortriptyline for Smoking Cessation Among People at Risk for or With Chronic Obstructive Pulmonary Disease. Arch Intern Med 2005; 165: 2286-2292
230. Hering T, Bölcskei P, Storz C et al. Strukturierte Raucherberatung und Tabakentwöhnung - Tabakentwöhnung in der Praxis-Sprechstunde (das Tabakentwöhnungskonzept des Bundesverbandes der Pneumologen in Deutschland - BDP). In: Vorträge der 5 Deutschen Nikotin Konferenz: ed. K. Haustein. Erfurt: Deutsche Gesellschaft für Nikotinforschung, 2002: 121-124
231. Moner M, Hey K, Lancaster T. Workplace interventions for smoking cessation. Cochrane Database Syst Rev, 2005: CD003440
232. Twardella D, Brenner H. Effects of practitioner education, practitioner payment and reimbursement of patients' drug costs on smoking cessation in primary care: a cluster randomised trial. Tobacco Control 2007; 16: 15-21
233. Silagy C, Lancaster T, Stead L et al. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev, 2004: CD000146
234. Organization WH. Regulation of Nicotine Replacement Therapies: An Expert Consensus. Copenhagen: Regional Office for Europe, 2001
235. Gonzales D, Rennard SI, Nides M et al. Varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs. sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. Jama 2006; 296: 47-55
236. Nides M, Oncken C, Gonzales D et al. Smoking cessation with varenicline, a selective α4β2 nicotinic receptor partial agonist: results from a 7-week, randomized, placebo- and bupropion-controlled trial with 1-year follow-up. Arch Intern Med 2006; 166: 1561-1568
237. Oncken C, Gonzales D, Nides M et al. Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation. Arch Intern Med 2006; 166: 1571-1577
238. Tonstad S, Tonnesen P, Hajek P et al. Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. Jama 2006; 296: 64-71
239. Jorenby DE, Hays JT, Rigotti NA et al. Efficacy of varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. Jama 2006; 296: 56-63
240. Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev, 2007: CD006103
241. Gourlay SG, Stead LF, Benowitz NL. Clonidine for smoking cessation. Cochrane Database Syst Rev, 2004: CD000058
242. Bundeszentrale fir gesundheitliche Aufklärung (BzgA). Kriterien guter Praxis in der Gesundheitsförderung bei sozial Benachteiligten. Köln, 2005
243. Morgan WJ. Maternal smoking and infant lung function. Further evidence for an in utero effect. Am J Respir Crit Care Med 1998; 158: 689-690
244. Ruff LK, Volmer T, Nowak D et al. The economic impact of smoking in Germany. Eur Respir J 2000; 16: 385-390
245. Parrott S, Godfrey C, Raw M. Costs of employee smoking in the workplace in Scotland. Tob Control 2000; 9: 187-192
246. Murray RP, Connett JE, Rand CS et al. Persistence of the effect of the Lung Health Study (LHS) smoking intervention over eleven years. Prev Med 2002; 35: 314-319
247. Raupach T, Shahab L, Neubert K et al. Implementing a hospital-based smoking cessation programme: Evidence for a learning effect. Patient Educ Couns 2008; 70: 199-204
248. Tengs TO, Adams ME, Pliskin JS et al. Five-hundred life-saving interventions and their cost-effectiveness. Risk Anal 1995; 15: 369-390
249. Thomas R, Perera R. School-based programmes for preventing smoking. Cochrane Database Syst Rev 2006; 3: CD001293
250. Seeker-Walker RH, Gnich W, Platt S et al. Community interventions for reducing smoking among adults. Cochrane Database Syst Rev, 2002: CD001745
251. Stead LF, Lancaster T. Group behaviour therapy programmes for smoking cessation. Cochrane Database Syst Rev, 2005: CD001007